Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 375,784 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the transaction, the director owned 15,127,329 shares in the company, valued at $400,874,218.50. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Daniel Allen Gold also recently made the following trade(s):

• On Wednesday, February 11th, Daniel Allen Gold sold 425,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.67, for a total transaction of $11,334,750.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The shares were sold at an average price of $23.07, for a total transaction of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The stock was sold at an average price of $23.04, for a total transaction of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total transaction of $26,299,000.00.

Roivant Sciences Price Performance

NASDAQ ROIV traded down $0.30 during trading on Friday, hitting $26.45. 4,357,971 shares of the company’s stock traded hands, compared to its average volume of 6,771,100. The stock has a fifty day moving average of $22.71 and a two-hundred day moving average of $18.31. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $27.94. The firm has a market cap of $18.40 billion, a P/E ratio of -22.61 and a beta of 1.22.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ROIV. Oregon Public Employees Retirement Fund boosted its holdings in Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after acquiring an additional 500 shares in the last quarter. Bank of Montreal Can raised its holdings in Roivant Sciences by 1.3% in the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after purchasing an additional 516 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Roivant Sciences by 15.8% during the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after purchasing an additional 588 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Key Headlines Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Wall Street Analysts Forecast Growth

ROIV has been the topic of several recent research reports. Citigroup raised their price target on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. The Goldman Sachs Group increased their price objective on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. HC Wainwright raised their target price on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.